Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer
NCT00344552
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
53
Enrollment
INDUSTRY
Sponsor class
Conditions
Esophageal Cancer
Interventions
DRUG:
Paclitaxel
Sponsor
Bristol-Myers Squibb